Karyopharm Therapeutics (KPTI)
(Real Time Quote from BATS)
$1.16 USD
+0.01 (0.87%)
Updated May 20, 2024 02:17 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 321 - 340 ( 386 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
SADAL Details at AACR Look Promising; Raising PT to $16 From $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Selinexor Durable Responses in DLBCL Supports Accelerated Approval Potential, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
4Q16: Selinexor Stays in the SADAL with Interim DLBCL Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
4Q/FY16, Encouraging Selinexor Response Rates in DLBCL, but Durability Will be Key, Looking for Additional Data at AACR, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Partial Clinical Hold Placed on Selinexor, but We Expect a Quick Resolution, No Change to our Outlook, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Win Some, Lose One: Selinexor Misses in AML, but Safety Profile Looks Cleaner Than Expected; PT From $15 to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
As Expected, a No-go for Selinexor in AML, DLBCL Data at AACR, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ASH Presentations Highlight Shifting Competitive Landscape in MM, We Like How Selinexor Is Positioned, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
3Q16: Cash and ASH Data Ahead of a Year of Possible Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
3Q, Near Term Catalysts in Place, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D